about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsAntibody Drug Conjugates: Preclinical ConsiderationsIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsRise and fall of an anti-MUC1 specific antibodyAcetyl-11-keto-β-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression.Prodrugs for improving tumor targetability and efficiency.Medicinal chemistry for 2020A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of DoxorubicinSite-specific antibody drug conjugates for cancer therapyResearch and development of next generation of antibody-based therapeuticsChallenges in developing bioanalytical assays for characterization of antibody-drug conjugates.Elastomeric polypeptides.Antibody-drug conjugates - a perfect synergy.Tumor endothelial markers as a target in cancer.Targeted drug delivery for cancer therapy: the other side of antibodies.Novel antibody-based proteins for cancer immunotherapy.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Antibody-mediated delivery of therapeutics for cancer therapy.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Ligand exchange on gold nanoparticles for drug delivery and enhanced therapeutic index evaluated in acute myeloid leukemia models.Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.Investigation of cancer cell lines for peptide receptor-targeted drug development.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.Current progress in innovative engineered antibodies.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsTumor-specific activation of an EGFR-targeting probody enhances therapeutic index.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.Site-Specific Antibody Conjugation for ADC and Beyond.Application of Immuno-PET in Antibody-Drug Conjugate Development
P2860
Q26800175-9CA275D1-E1E8-4BFD-A844-C3E49ADE0FC5Q27022321-02ABC4A0-DF03-4B9C-B10B-B4FFD73BE210Q28544645-79ADDE12-119B-4016-B151-E53B79D29F35Q28743508-9A0812F6-BBD0-429E-B1DA-E87A675B8C46Q34861014-93492F6F-9993-4F90-9E06-B916F8D1CA16Q35095165-FCA0AC9E-192B-472B-83DF-7C8EA0714DC2Q35593223-30482832-C542-4C81-B759-FF4365EEE71AQ35764587-4A185B3F-508F-4B60-8B20-76456675C332Q36142511-280CBD21-A7DB-454D-ADD7-1A9C81414240Q36446685-83E77BBC-4AE8-4C16-B576-98F09CB28ECAQ37593705-E64B760A-2014-4074-B8B7-E108A16F65F3Q37778732-D92ED224-C117-484B-A38D-C8FC66F1110DQ37854644-0DAFC148-158F-41B4-AAC9-A7383F8A03D2Q37914083-72F11F30-F2DF-4BB3-AA72-A2102FE6FDDDQ38014923-063486B5-6172-4D5D-8944-DC6D9EDD5AE0Q38043525-036F5004-B0B8-467D-AC86-2BC4ED566BB1Q38058816-EFB786B7-FA41-45BD-9318-ED9536A81C09Q38161370-751C4D96-F81D-4B7A-829F-A1963D4F84B8Q38453769-92DE7DDD-F906-4E22-A466-A3B7FBFC0FFCQ38648690-565F9342-5BB2-4669-89A3-8B387FEA9010Q38665425-6F6CF3A2-1F63-4B80-864C-9E776F854E6CQ38865705-BCA32FA4-3198-4AB4-A1A4-D156024F6268Q38920359-BEA52FB3-0CA1-4E44-94F2-E9D36EBC8D1BQ38989899-4A049B38-4D53-4461-A4D5-991BA9C36173Q38998238-86D414DB-A3A3-4E60-8C6F-8EFC812ADF3AQ39298392-6907711C-065A-46E9-9F09-C89B618A5C02Q39310345-9CED13BB-CDC3-4B11-8BBB-2FD908350C3DQ39492350-10A420DF-B40A-4BEE-8D23-732A9946CC86Q39564060-7977DD1F-1137-4233-833C-60BCDC06681DQ39630765-108FC91E-C568-42C9-A448-EF7B115760B5Q40077818-81835A6A-7C2B-4409-B5B4-409167751582Q42333450-3A958437-A2CA-4685-B6E0-DF9B10F2EE1EQ42755952-B937F352-30E8-4486-BFF7-72F395F13AEEQ44705970-EED8B1AC-E0D1-4A64-9F95-98A5E4A4F325Q50865530-A1372D2D-510D-4D7E-ADE5-0475F67999DBQ51132501-263BA806-FB49-4D40-B584-55DC616711C4Q55022669-30ECF2B9-E990-4CA4-8828-E1927B70DF32Q58132996-7AA96649-DEC7-4E38-B230-DC8F6C93A609
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antibody-drug conjugate targets.
@en
Antibody-drug conjugate targets.
@nl
type
label
Antibody-drug conjugate targets.
@en
Antibody-drug conjugate targets.
@nl
prefLabel
Antibody-drug conjugate targets.
@en
Antibody-drug conjugate targets.
@nl
P1476
Antibody-drug conjugate targets.
@en
P2093
Teicher BA
P304
P356
10.2174/156800909790192365
P577
2009-12-01T00:00:00Z